[  What’s new  ]

Latest News

April 20, 2026

AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs

Daniel Chen, M.D., Ph.D., once global head of cancer immunotherapy development at Genentech, has officially launched Synthetic Design Lab (SDL) — a Bay Area biotech engineering the next generation of antibody-drug conjugates (ADCs) that adapt as cancer evolves.

In the News
read
[  more news  ]
all
Select Category
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
April 18, 2026

Synthbody™- A novel multivalent multispecific antibody drug conjugate platform demonstrates combinatorial logic-gated “synthetic” targeting of cancer antigens with log order enhanced internalization and potency

Antibody Drug Conjugates (ADCs), such as trastuzumab deruxtecan, achieve complete responses >20% and duration of response >30 months in patients with metastatic Her2+ breast cancer1.

Insights
read
May 13, 2026

Daniel Chen on The CHAIN Protein Engineering Podcast #85

Listen to Daniel Chen discuss Building Multi-Target Drugs with Logic Gating on episode #85 of The CHAIN with Host Andrew Bradbury.

In the News
read
May 14, 2026

22nd Annual PEGS Boston Presentation by Ramesh Baliga

Ramesh Baliga presents Synthetic Targets Using SYNTHBODY, a Novel Multivalent Multispecific Antibody-Drug Conjugate Platform That Utilizes Multi-Tiered Logic-Gated Control, Demonstrating Log-Order Increased Internalization and Potency at PEGS Boston.

Insights
read
April 20, 2026

AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs

Daniel Chen, M.D., Ph.D., once global head of cancer immunotherapy development at Genentech, has officially launched Synthetic Design Lab (SDL) — a Bay Area biotech engineering the next generation of antibody-drug conjugates (ADCs) that adapt as cancer evolves.

In the News
read
April 22, 2025

Genentech vet launches ADC startup with $20M

A Bay Area protein design startup wants to build more potent antibody-drug conjugates, and is starting with $20 million in seed funding.

In the News
read
April 22, 2025

Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs

Company is led by cancer immunotherapy and protein engineering pioneer Daniel S. Chen, M.D., Ph.D. SYNTHBODY™ platform increases targeted payload delivery ≥10x compared to current ADCs; expects to enter the clinic in 2026

Announcements
read
April 19, 2026

Synthetic Design Lab Unveils First Advanced Logic-Gated ADC at AACR 2026, Achieving ≥10X Improvement in Targeted Cancer Cell Killing

SYNTHBODY™ introduces a new class of "smart drugs": protein therapeutics with built-in, multi-layered logic gates that actively change how they behave based on what they encounter in the body, a capability previously unseen in any approved protein drug

Announcements
read
April 22, 2025

In Brief: Synthetic Design Lab Debuts With $20m To Advance Cutting-Edge ADCs

As ADCs continue to be a growth area globally, a new US-based venture with novel platform technology has emerged from stealth mode with $20m in funding.

In the News
read
June 14, 2025

Biotech financing: divide and reset

Today’s uniquely challenging biotech climate may result in a more resilient sector.

In the News
read
April 22, 2025

Genentech alum’s Synthetic Design Lab raises $20 million to fight cancer

The CEO previously helped develop a breakthrough cancer immunotherapy drug.

In the News
read

Precision Built for What’s Next in Medicine

Explore SYNTHBODY™